News | March 04, 2025
Biocon Academy conducts 9th Graduation Day
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Subscribe To Our Newsletter & Stay Updated
